UNSPSC 51292101: Danitracen

This classification denotes a serotonin antagonist with the molecular formula C20H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SD507F5T2W, chemically known as 9,10-dihydro-10-(1-methyl-4-piperidylidene)-9-anthrol but generally known as danitracen, which bears US NIH Compound Identifier 35758. European Medicines Agency schedules Danitracen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06900MIG.

UNSPSC 51292101 Danitracen, a Commodity code, covers pharmaceutical products including naloxone and other drug-related therapeutics that state and local health agencies procure for community health and emergency response programs. State and local governments soliciting under this code include county health departments, state health and human services commissions, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions and participating entities. The work involves purchasing finished pharmaceutical products—naloxone for overdose reversal, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products—with delivery to health facilities, community health centers, and authorized wholesalers, all subject to FDA compliance, Good Manufacturing Practices certification, Drug Supply Chain Security Act adherence, and specific insurance and employment-eligibility requirements.

Recent activity spans Florida and Texas, with coordinated multi-state procurement through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP). Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; responses were due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting with manufacturers outside existing pharmacy benefit manager arrangements. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contracts effective July 1, 2026; vendors must maintain relationships with authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, and comply with $5,000,000 commercial general liability and $2,000,000 network security and professional liability insurance requirements.